Protein kinase inhibitors of the quinazoline class exert anti-cytomegaloviral activity in vitro and in vivo

Antiviral Research

Volumn 79, Issue 1, 2008, Pages 49-61

  Schleiss, Mark ^b   Eickhoff, Jan ^c   Auerochs, Sabrina ^a   Leis, Martina ^a   Abele, Silke ^d   Rechter, Sabine ^a   Choi, Yeon ^b   Anderson, Jodi ^b   Scott, Gillian ^f,g   Rawlinson, William ^f,g   Michel, Detlef ^e   Ensminger, Stephan ^d   Klebl, Bert ^c   Stamminger, Thomas ^a   Marschall, Manfred ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c GPC Biotech AG   (Germany)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^e UNIVERSITY OF ULM   (Germany)

^f SEALS   (Australia)

^g UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Animal models; Antiviral activity; Drug development; Human cytomegalovirus; Mode of action; Protein kinase inhibitors

Indexed keywords

AX 7396; CIDOFOVIR; CYCLOPHOSPHAMIDE; ERLOTINIB; GANCICLOVIR; GEFITINIB; PACLITAXEL; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; RGB 315389; STAUROSPORINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DRUG STRUCTURE; GUINEA PIG; HUMAN; HUMAN CELL; IC 50; IMMUNOCOMPROMISED PATIENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; CELL SURVIVAL; CELLS, CULTURED; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GUINEA PIGS; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICE; PHOSPHOTRANSFERASES; PLAQUE ASSAY; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RATS; SEQUENCE DELETION; VIRAL LOAD; VIRAL PROTEINS;

ANIMALIA; CAVIA; CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 43049103744     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.01.154     Document Type: Article

References (43)

1. Baek M.C., Krosky P.M., Pearson A., and Coen D.M. Phosphorylation of the RNA polymerase II carboxyl-terminal domain in human cytomegalovirus-infected cells and in vitro by the viral UL97 protein kinase. Virology 324 (2004) 184-193
2. Bergman E., Forsell P., Persson E.M., Knutson L., Dickinson P., Smith R., Swaisland H., Farmer M.R., Cantarini M.V., and Lennernäs H. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. Int. J. Pharm. 341 (2007) 134-142
3. Biron K.K., Fyfe J.A., Stanat S.C., Leslie L.K., Sorrell J.B., Lambe C.U., and Coen D.M. A human cytomegalovirus mutant resistant to the nucleoside analog 9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}guanine (BW B759U) induces reduced levels of BW B759U triphosphate. Proc. Natl. Acad. Sci. U.S.A. 83 (1986) 8769-8773
4. Biron K.K., Harvey R.J., Chamberlain S.C., Good S.S., Smith III A.A., Davis M.G., Talarico C.L., Miller W.H., Ferris R., Dornsife R.E., Stanat S.C., Drach J.C., Townsend L.B., and Koszalka G.W. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46 (2002) 2365-2372
5. Brehmer D., Greff Z., Godl K., Blencke S., Kurtenbach A., Weber M., Müller S., Klebl B., Cotten M., Kéri G., Wissing J., and Daub H. Cellular targets of gefitinib. Cancer Res. 65 (2005) 379-382
6. Buschbeck M. Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer. Drugs R D 7 (2006) 73-86
7. Castoldi R.E., Pennella G., Saturno G.S., Grossi P., Brughera M., and Venturi M. Assessing and managing toxicities induced by kinase inhibitors. Curr. Opin. Drug Discov. Dev. 10 (2007) 53-57
8. Chou S., Marousek G.I., Senters A.E., Davis M.G., and Biron K.K. Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J. Virol. 78 (2004) 7124-7130
9. Chou S., Wechel L.C., and Marousek G.I. Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. J. Infect. Dis. 196 (2007) 91-94
10. Cohen M.H., Williams G.A., Sridhara R., Chen G., and Pazdur R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist 8 (2003) 303-306
11. Fortunato E.A., McElroy A.K., Sanchez I., and Spector D.H. Exploitation of cellular signaling and regulatory pathways by human cytomegalovirus. Trends Microbiol. 8 (2000) 111-119
12. Herbst R.S., Fukuoka M., and Baselga J. Gefitinib-a novel targeted approach to treating cancer. Nat. Rev. Cancer 4 (2004) 956-965
13. Heredia A., Davis C., Bamba D., Le N., Gwarzo M.Y., Sadowska M., Gallo R.C., and Redfield R.R. Indirubin-3′-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS 19 (2005) 2087-2095
14. Herget T., and Marschall M. Recent developments in anti-herpesviral combination therapy based on protein kinase inhibitors. In: Holzenburg A., and Bogner E. (Eds). New Concepts of Antiviral Therapy (2006), Springer, London, UK 351-371
15. Herget T., Freitag M., Morbitzer M., Kupfer R., Stamminger T., and Marschall M. A novel chemical class of pUL97 protein kinase-specific inhibitors with strong anti-cytomegaloviral activity. Antimicrob. Agents Chemother. 48 (2004) 4154-4162
16. Isaacson M.K., Feire A.L., and Compton T. Epidermal growth factor is not required for human cytomegalovirus entry or signaling. J. Virol. 81 (2007) 6241-6247
17. Kaptein J.F., Efferth T., Leis M., Rechter S., Auerochs S., Kalmer M., Bruggeman C.A., Vink C., Stamminger T., and Marschall M. The anti-malaria drug artesunate inhibits replication of cytomegalovirus in vitro and in vivo. Antiviral Res. 69 (2006) 60-69
18. Kawaguchi Y., Kato K., Tanaka M., Kanamori M., Nishiyama Y., and Yamanashi Y. Conserved protein kinases encoded by herpesviruses and cellular protein kinase cdc2 target the same phosphorylation site in eukaryotic elongation factor 1delta. J. Virol. 77 (2003) 2359-2368
19. Koszalka G.W., Johnson N.W., Good S.S., Boyd L., Chamberlain S.C., Townsend L.B., Drach J.C., and Biron K.K. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 46 (2002) 2373-2380
20. Krosky P.M., Baek M.C., Jahng W.J., Barrera I., Harvey R.J., Biron K.K., Coen D.M., and Sethna P.B. The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J. Virol. 77 (2003) 7720-7727
21. Lalezari J.P., Aberg J.A., Wang L.H., Wire M.B., Miner R., Snowden W., Talarico C.L., Shaw S., Jacobson M.A., and Drew W.L. Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46 (2002) 2969-2976
22. Marschall M., Freitag M., Weiler S., Sorg G., and Stamminger T. Recombinant green fluorescent protein-expressing human cytomegalovirus as a tool for screening antiviral agents. Antimicrob. Agents Chemother. 44 (2000) 1588-1597
23. Marschall M., Stein-Gerlach M., Freitag M., Kupfer R., van den Bogaard M., and Stamminger T. Inhibitors of human cytomegalovirus replication drastically reduce the activity of the viral protein kinase pUL97. J. Gen. Virol. 82 (2001) 1439-1450
24. Marschall M., Stein-Gerlach M., Freitag M., Kupfer R., van den Bogaard M., and Stamminger T. Direct targeting of human cytomegalovirus protein kinase pUL97 by kinase inhibitors is a novel principle for antiviral therapy. J. Gen. Virol. 83 (2002) 1013-1023
25. Marschall M., Freitag M., Suchy P., Romaker D., Kupfer R., Hanke M., and Stamminger T. The protein kinase pUL97 of human cytomegalovirus interacts with and phosphorylates the DNA polymerase processivity factor pUL44. Virology 311 (2003) 60-71
26. Marschall M., Marzi A., aus dem Siepen P., Jochmann R., Kalmer M., Auerochs S., Lischka P., Leis M., and Stamminger T. Cellular p32 recruits cytomegalovirus kinase pUL97 to redistribute the nuclear lamina. J. Biol. Chem. 280 (2005) 33357-33367
27. Mathys S., Schroeder T., Ellwart J., Koszinowski U.H., Messerle M., and Just U. Dendritic cells under influence of mouse cytomegalovirus have a physiologic dual role: to initiate and to restrict T cell activation. J. Infect. Dis. 187 (2003) 988-999
28. McGregor A., and Schleiss M.R. Molecular cloning of the guinea pig cytomegalovirus (GPCMV) genome as an infectious bacterial artificial chromosome (BAC) in Escherichia coli. Mol. Genet. Metab. 72 (2001) 15-26
29. Mett H., Hölscher K., Degen H., Esdar C., De Neumann B.F., Flicke B., Freudenreich T., Holzer G., Schinzel S., Stamminger T., Stein-Gerlach M., Marschall M., and Herget T. Identification of inhibitors for a virally encoded protein kinase by 2 different screening systems: in vitro kinase assay and in-cell activity assay. J. Biomol. Screen 10 (2005) 36-45
30. Mocarski E.S., Shenk T., and Pass R.F. Cytomegaloviruses. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology. Fifth ed. (2007), Wolters Kluwer, Lippincott Williams & Wilkins 2701-2772
31. Ono M., and Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin. Cancer Res. 12 (2006) 7242-7251
32. Rechter S., König T., Auerochs S., Thulke S., Walter H., Dörnenburg H., Walter C., and Marschall M. Antiviral activity of arthrospira-derived spirulan-like substances. Antiviral Res. 7 (2006) 197-206
33. Romaker D., Schregel V., Maurer K., Auerochs S., Marzi A., Sticht H., and Marschall M. Analysis of the structure-activity relationship of four herpesviral UL97 subfamily protein kinases reveals partial but not full functional conservation. J. Med. Chem. 49 (2006) 7044-7053
34. Schang L.M., St. Vincent M.R., and Lacasse J.J. Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs. Antiviral Chem. Chemother. 17 (2006) 293-320
35. Scott G.M., Ng H.L., Morton C.J., Parker M.W., and Rawlinson W.D. Murine cytomegalovirus resistant to antivirals has genetic correlates with human cytomegalovirus. J. Gen. Virol. 86 (2005) 2141-2151
36. Sportsman J.R., Gaudet E.A., and Boge A. Immobilized metal ion affinity-based fluorescence polarization (IMAP): advances in kinase screening. Assay Drug Dev. Technol. 2 (2004) 205-214
37. Sullivan V., Talarico C.L., Stanat S.C., Davis M., Coen D.M., and Biron K.K. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 358 (1992) 162-164
38. Sullivan V., Biron K.K., Talarico C., Stanat S.C., Davis M., Pozzi L.M., and Coen D.M. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob. Agents Chemother. 37 (1993) 19-25
39. Wagner M., Michel D., Schaarschmidt P., Vaida B., Jonjic S., Messerle M., Mertens T., and Koszinowski U. Comparison between human cytomegalovirus pUL97 and murine cytomegalovirus (MCMV) pM97 expressed by MCMV and vaccinia virus: pM97 does not confer ganciclovir sensitivity. J. Virol. 74 (2000) 10729-10736
40. Wakeling A.E., Guy S.P., Woodburn J.R., Ashton S.E., Curry B.J., Barker A.J., and Gibson K.H. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62 (2002) 5749-5754
41. Wang L.H., Peck R.W., Yin Y., Allanson J., Wiggs R., and Wire M.B. Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 47 (2003) 1334-1342
42. Wang X., Huong S.M., Chiu M.L., Raab-Traub N., and Huang E.S. Epidermal growth factor receptor is a cellular receptor for human cytomegalovirus. Nature 424 (2003) 456-461
43. Zimmermann A., Wilts H., Lenhardt M., Hahn M., and Mertens T. Indolocarbazoles exhibit strong antiviral activity against human cytomegalovirus and are potent inhibitors of the pUL97 protein kinase. Antiviral Res. 48 (2000) 49-60